Intravenous immunoglobulin: adverse effects and safe administration.

PubWeight™: 1.52‹?› | Rank: Top 4%

🔗 View Article (PMID 16391392)

Published in Clin Rev Allergy Immunol on December 01, 2005

Authors

Hedi Orbach1, Uriel Katz, Yaniv Sherer, Yehuda Shoenfeld

Author Affiliations

1: Department of Medicine B, Wolfson Medical Center, Holon, Israel.

Associated clinical trials:

IVIG in Acute Ischemic Stroke: A Pilot Study (IVIG/AIS) | NCT01628055

Articles citing this

The hyperferritinemic syndrome: macrophage activation syndrome, Still's disease, septic shock and catastrophic antiphospholipid syndrome. BMC Med (2013) 1.56

Intravenous immunoglobulin (IVIG) protects the brain against experimental stroke by preventing complement-mediated neuronal cell death. Proc Natl Acad Sci U S A (2007) 1.46

Neuroprotection in stroke by complement inhibition and immunoglobulin therapy. Neuroscience (2008) 1.16

International Consensus Document (ICON): Common Variable Immunodeficiency Disorders. J Allergy Clin Immunol Pract (2015) 1.11

Aseptic meningitis following intravenous immunoglobulin therapy of common variable immunodeficiency. J Pediatr Neurosci (2011) 1.05

Fetal intraperitoneal injection of immunoglobulin diminishes alloimmune hemolysis. J Perinatol (2011) 0.98

ABO incompatible renal transplants: Good or bad? World J Transplant (2014) 0.97

Carimune NF Liquid is a safe and effective immunoglobulin replacement therapy in patients with primary immunodeficiency diseases. J Clin Immunol (2007) 0.97

Using intravenous immunoglobulin (IVIG) to treat patients with primary immune deficiency disease. J Clin Immunol (2012) 0.92

Clinical characteristics of aseptic meningitis induced by intravenous immunoglobulin in patients with Kawasaki disease. Pediatr Rheumatol Online J (2011) 0.89

Safety of high-dose intravenous immunoglobulin in systemic autoimmune diseases. Clin Rheumatol (2007) 0.82

Toxicities of immunosuppressive treatment of autoimmune neurologic diseases. Curr Neuropharmacol (2011) 0.82

The spectrum of renal involvement in patients with inflammatory myopathies. Medicine (Baltimore) (2014) 0.81

On the dark side of therapies with immunoglobulin concentrates: the adverse events. Front Immunol (2015) 0.81

Tregitope peptides: the active pharmaceutical ingredient of IVIG? Clin Dev Immunol (2013) 0.80

Treatment of proliferative lupus nephritis: a slowly changing landscape. Nat Rev Nephrol (2010) 0.79

Immune mediated diseases and immune modulation in the neurocritical care unit. Neurotherapeutics (2012) 0.78

Use of intravenous immunoglobulin in a disseminated varicella infection in an immunocompromised child. Korean J Pediatr (2014) 0.78

Emerging Paradigm of Primary Immunodeficiency Disease: Individualizing Immunoglobulin Dose and Delivery to Enhance Outcomes. J Clin Immunol (2014) 0.77

Indications for IVIG in rheumatic diseases. Rheumatology (Oxford) (2014) 0.77

Phase I clinical study of RG7356, an anti-CD44 humanized antibody, in patients with acute myeloid leukemia. Oncotarget (2016) 0.77

Redimune NF Liquid, a ready-to-use, high-concentration intravenous immunoglobulin therapy preparation, is safe and typically well tolerated in the routine clinical management of a broad range of conditions. Clin Exp Immunol (2008) 0.77

Primary IgA and IgG subclass deficiency in a 17-year-old Pakistani girl: a case report. Cases J (2009) 0.75

Patient-reported treatment burden of chronic immune thrombocytopenia therapies. BMC Blood Disord (2012) 0.75

The role of intravenous immunoglobulin in treatment of mucous membrane pemphigoid: A review of literature. J Res Med Sci (2016) 0.75

Severe periodontal disease associated with long-term treatment with intravenous immunoglobulin. Case Rep Dent (2014) 0.75

Dosing and therapy utilization: a discussion of updates on PI treatment guidelines. J Clin Immunol (2012) 0.75

High-resolution physicochemical characterization of different intravenous immunoglobulin products. PLoS One (2017) 0.75

Treatment of Juvenile Dermatomyositis: An Update. Paediatr Drugs (2017) 0.75

IVIG-Associated Maternal Pancytopenia during Treatment for Neonatal Alloimmune Thrombocytopenia. AJP Rep (2017) 0.75

Surveillance study on the tolerability and safety of Flebogamma(®) DIF (10% and 5% intravenous immunoglobulin) in adult and pediatric patients. Pharmacol Res Perspect (2017) 0.75

SCIg vs. IVIg: let's give patients the choice! J Clin Immunol (2014) 0.75

Articles by these authors

Antiphospholipid syndrome: clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients. Arthritis Rheum (2002) 5.12

International recommendations for the assessment of autoantibodies to cellular antigens referred to as anti-nuclear antibodies. Ann Rheum Dis (2013) 3.99

Human papilloma virus vaccine and primary ovarian failure: another facet of the autoimmune/inflammatory syndrome induced by adjuvants. Am J Reprod Immunol (2013) 3.42

Pathogenesis and natural history of osteonecrosis. Semin Arthritis Rheum (2002) 3.30

Autoantibody explosion in systemic lupus erythematosus: more than 100 different antibodies found in SLE patients. Semin Arthritis Rheum (2004) 3.23

Vitamin D effects on musculoskeletal health, immunity, autoimmunity, cardiovascular disease, cancer, fertility, pregnancy, dementia and mortality-a review of recent evidence. Autoimmun Rev (2013) 2.87

HIV and autoimmunity. Autoimmun Rev (2002) 2.83

Vitamin D and autoimmunity: new aetiological and therapeutic considerations. Ann Rheum Dis (2007) 2.76

Measurement of electrical skin impedance of dermal-visceral zones as a diagnostic tool for inner organ pathologies: a blinded preliminary evaluation of a new technique. Isr Med Assoc J (2005) 2.57

Effects of tobacco smoke on immunity, inflammation and autoimmunity. J Autoimmun (2009) 2.49

Vitamin D and musculoskeletal health, cardiovascular disease, autoimmunity and cancer: Recommendations for clinical practice. Autoimmun Rev (2010) 2.38

Vaccination may be associated with autoimmune diseases. Isr Med Assoc J (2004) 2.14

Functional class in patients with heart failure is associated with the development of diabetes. Am J Med (2003) 2.10

Caring for the caregivers. J Travel Med (2006) 2.04

Accelerated atherosclerosis in autoimmune rheumatic diseases. Circulation (2005) 2.03

The Lancet against Israel. Isr Med Assoc J (2013) 2.03

Intensive lipid-lowering therapy: obvious benefits, possible risks. Isr Med Assoc J (2006) 2.02

The role of inflammatory cytokines in the pathogenesis of systemic lupus erythematosus-related atherosclerosis: a novel target for treatment? J Rheumatol (2006) 1.79

Catastrophic antiphospholipid syndrome (CAPS): descriptive analysis of a series of 280 patients from the "CAPS Registry". J Autoimmun (2009) 1.78

Anti-inflammatory and immunosuppressive drugs and reproduction. Arthritis Res Ther (2006) 1.78

Systemic lupus erythematosus in a multiethnic US cohort (LUMINA). XXIII. Baseline predictors of vascular events. Arthritis Rheum (2004) 1.75

Association between vaccination and Guillain-Barré syndrome. Lancet Infect Dis (2013) 1.69

Vitamin D insufficiency in a sunny environment: a demographic and seasonal analysis. Isr Med Assoc J (2010) 1.68

Defining and analyzing geoepidemiology and human autoimmunity. J Autoimmun (2010) 1.67

Matrix metalloproteinase-9 and autoimmune diseases. J Clin Immunol (2006) 1.66

Intravenous immunoglobulin therapy affects T regulatory cells by increasing their suppressive function. J Immunol (2007) 1.64

Assessment of subclinical vascular disease associated with ankylosing spondylitis. J Rheumatol (2011) 1.62

The geoepidemiology of systemic lupus erythematosus. Autoimmun Rev (2009) 1.57

The antiphospholipid syndrome as a neurological disease. Semin Arthritis Rheum (2009) 1.57

The hyperferritinemic syndrome: macrophage activation syndrome, Still's disease, septic shock and catastrophic antiphospholipid syndrome. BMC Med (2013) 1.56

Helicobacter pylori serology in autoimmune diseases - fact or fiction? Clin Chem Lab Med (2013) 1.56

The role of CD40-CD154 interactions in autoimmunity and the benefit of disrupting this pathway. Autoimmunity (2004) 1.54

Gender and autoimmunity. Autoimmun Rev (2006) 1.54

Erdheim-Chester Disease: a comprehensive review of the literature. Orphanet J Rare Dis (2013) 1.54

Hydroxychloroquine: from malaria to autoimmunity. Clin Rev Allergy Immunol (2012) 1.53

Inflammatory bowel disease: adverse effect of isotretinoin. Isr Med Assoc J (2009) 1.51

Mechanisms of disease: atherosclerosis in autoimmune diseases. Nat Clin Pract Rheumatol (2006) 1.46

Thymoma and autoimmunity. Cell Mol Immunol (2011) 1.44

Novel aspects of Sjögren's syndrome in 2012. BMC Med (2013) 1.44

IL-2 receptor alpha deficiency and features of primary biliary cirrhosis. J Autoimmun (2006) 1.43

Late ventricular potentials and QT dispersion in familial dysautonomia. Pediatr Cardiol (2009) 1.42

Intelligent nutrition: health-promoting mechanisms of probiotics. Isr Med Assoc J (2003) 1.42

The changing face of Lemierre's syndrome. Isr Med Assoc J (2003) 1.41

Endothelial dysfunction: a crystal ball prediction for enhanced cardiovascular risk? Isr Med Assoc J (2003) 1.41

Safety of intravenous immunoglobulin (IVIG) therapy. Autoimmun Rev (2006) 1.39

Systemic thromboembolism in inflammatory bowel disease: mechanisms and clinical applications. Ann N Y Acad Sci (2005) 1.39

Hippocrates' Oath is challenged. Isr Med Assoc J (2009) 1.38

Infections and SLE. Autoimmunity (2005) 1.38

CD4+CD28- T lymphocytes contribute to early atherosclerotic damage in rheumatoid arthritis patients. Circulation (2004) 1.36

Accelerated atherosclerosis in rheumatoid arthritis. Ann N Y Acad Sci (2007) 1.36

Infection, vaccines and other environmental triggers of autoimmunity. Autoimmunity (2005) 1.36

Lupus nephritis: a critical review. Autoimmun Rev (2012) 1.36

Schizophrenia, autoimmunity and immune system dysregulation: a comprehensive model updated and revisited. J Autoimmun (2006) 1.35

Parotitis as the presenting symptom of Wegener's granulomatosis: case report and meta-analysis. Isr Med Assoc J (2013) 1.35

What is the contents of the magic draft IVIg? Autoimmun Rev (2008) 1.31

Neuropsychiatric syndromes in systemic lupus erythematosus: a meta-analysis. Semin Arthritis Rheum (2010) 1.31

Infections and autoimmunity--friends or foes? Trends Immunol (2009) 1.31

Endothelial dysfunction and atherosclerosis in rheumatoid arthritis: a multiparametric analysis using imaging techniques and laboratory markers of inflammation and autoimmunity. J Rheumatol (2008) 1.29

Pathogenesis of infertility and recurrent pregnancy loss in thyroid autoimmunity. J Autoimmun (2012) 1.28

Vitamin D and autoimmune thyroid diseases. Cell Mol Immunol (2011) 1.28

Autoantibodies involved in neuropsychiatric SLE and antiphospholipid syndrome. Semin Arthritis Rheum (2007) 1.27

The autoimmune bases of infertility and pregnancy loss. J Autoimmun (2012) 1.27

A novel automated indirect immunofluorescence autoantibody evaluation. Clin Rheumatol (2011) 1.27

Novel biomarkers in autoimmune diseases: prolactin, ferritin, vitamin D, and TPA levels in autoimmune diseases. Ann N Y Acad Sci (2007) 1.26

Sjögren's syndrome, the old and the new. Best Pract Res Clin Rheumatol (2012) 1.25

Precocious intima-media thickening in patients with primary Sjögren's syndrome. Arthritis Rheum (2005) 1.25

Practical guidelines for the supplementation of vitamin D and the treatment of deficits in Central Europe - recommended vitamin D intakes in the general population and groups at risk of vitamin D deficiency. Endokrynol Pol (2013) 1.25

Validated methods for assessment of subclinical atherosclerosis in rheumatology. Nat Rev Rheumatol (2012) 1.23

Vitamin D in systemic and organ-specific autoimmune diseases. Clin Rev Allergy Immunol (2013) 1.23

Protective molecules--C-reactive protein (CRP), serum amyloid P (SAP), pentraxin3 (PTX3), mannose-binding lectin (MBL), and apolipoprotein A1 (Apo A1), and their autoantibodies: prevalence and clinical significance in autoimmunity. J Clin Immunol (2005) 1.23

Biologic therapy for autoimmune diseases: an update. BMC Med (2013) 1.23

Surviving the butterfly and the wolf: mortality trends in systemic lupus erythematosus. Autoimmun Rev (2004) 1.22

Helicobacter pylori reinfection is common in Peruvian adults after antibiotic eradication therapy. J Infect Dis (2003) 1.21

Bacterial induction of autoantibodies to beta2-glycoprotein-I accounts for the infectious etiology of antiphospholipid syndrome. J Clin Invest (2002) 1.19

Hepatitis B virus (HBV) and autoimmune disease. Clin Rev Allergy Immunol (2008) 1.19

Induction of autoimmune depression in mice by anti-ribosomal P antibodies via the limbic system. Arthritis Rheum (2007) 1.19

Autoimmune/inflammatory syndrome induced by adjuvants (ASIA) 2013: Unveiling the pathogenic, clinical and diagnostic aspects. J Autoimmun (2013) 1.19

Juvenile idiopathic arthritis. Autoimmun Rev (2005) 1.18

Are anti-ribosomal P protein antibodies relevant in systemic lupus erythematosus? Clin Rev Allergy Immunol (2007) 1.18

SLE and infections. Clin Rev Allergy Immunol (2003) 1.17

The idiotypic network in autoimmunity: antibodies that bind antibodies that bind antibodies. Nat Med (2004) 1.17

The infectious etiology of vasculitis. Autoimmunity (2009) 1.16

Hyperprolactinemia and autoimmune diseases. Autoimmun Rev (2006) 1.15

The kaleidoscope of autoimmunity: multiple autoimmune syndromes and familial autoimmunity. Expert Rev Clin Immunol (2007) 1.15

Autoimmune/inflammatory syndrome induced by adjuvants (Shoenfeld's syndrome): clinical and immunological spectrum. Expert Rev Clin Immunol (2013) 1.14

Osteonecrosis in patients with SLE. Clin Rev Allergy Immunol (2003) 1.14

Effects of rituximab treatment on endothelial dysfunction, carotid atherosclerosis, and lipid profile in rheumatoid arthritis. Clin Rheumatol (2009) 1.13

Molecular mimicry and auto-immunity. Clin Rev Allergy Immunol (2007) 1.12

Oral tolerance with heat shock protein 65 attenuates Mycobacterium tuberculosis-induced and high-fat-diet-driven atherosclerotic lesions. J Am Coll Cardiol (2002) 1.12

Mixed connective tissue disease: an overview of clinical manifestations, diagnosis and treatment. Best Pract Res Clin Rheumatol (2012) 1.12

Toll-like receptors and their role in the development of autoimmune diseases. Autoimmunity (2004) 1.12

Harnessing autoimmunity (vitiligo) to treat melanoma: a myth or reality? Ann N Y Acad Sci (2007) 1.11

Post-influenza vaccination vasculitides: a possible new entity. J Clin Rheumatol (2009) 1.11

Tobacco smoking and autoimmune rheumatic diseases. Nat Clin Pract Rheumatol (2007) 1.11

Intravenous immunoglobulin and the kidney--a two-edged sword. Semin Arthritis Rheum (2004) 1.11